PDCD1 and head and neck squamous cell carcinoma: This trial evaluated pembrolizumab in patients with R/M HNSCC and demonstrated early evidence of efficacy, with an ORR of 18% and durable responses, paving the way for further development of PD-1 inhibitors in HNSCC [103,104].